Načítá se...
Sodium‐glucose co‐transporter‐2 inhibitors with and without metformin: A meta‐analysis of cardiovascular, kidney and mortality outcomes
AIM: To assess whether the effects of sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors on cardiovascular, kidney and mortality outcomes are consistent with and without concomitant metformin use. MATERIAL AND METHODS: We conducted a meta‐analysis of event‐driven, randomized, placebo‐controlled SGLT...
Uloženo v:
| Vydáno v: | Diabetes Obes Metab |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Blackwell Publishing Ltd
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7821162/ https://ncbi.nlm.nih.gov/pubmed/33043620 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.14226 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|